SEOM clinical guideline for the management of malignant melanoma (2017)
Clin. transl. oncol. (Print)
; 20(1): 69-74, ene. 2018. tab
Artigo
em Inglês
| IBECS
| ID: ibc-170469
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams (AU)
RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Cutâneas
/
Melanoma
Tipo de estudo:
Guia de prática clínica
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clínica Universitaria de Navarra/Spain
/
Complejo Hospitalario Regional Virgen Macarena/Spain
/
Consorcio Hospital General Universitario de Valencia/Spain
/
Hospital Clinic I Provincial de Barcelona/Spain
/
Hospital General Universitario Gregorio Marañón/Spain
/
Hospital Torrecárdenas/Spain
/
Hospital Universitario Clínico San Carlos/Spain
/
Hospital Universitario Quirón Dexeus/Spain
/
Hospital Universitario Ramón y Cajal/Spain
/
Hospital Universitario la Paz/Spain
